NewAmsterdam Pharma Announces Phase 3 BROOKLYN Trial Results For Obicetrapib In Reducing LDL-C
Portfolio Pulse from Benzinga Newsdesk
NewAmsterdam Pharma announced positive Phase 3 BROOKLYN trial results for Obicetrapib, showing significant reductions in LDL-C levels at both Day 84 and Day 365. The drug was well-tolerated with safety comparable to placebo. A conference call is scheduled for 8:30 AM ET today.
July 29, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NewAmsterdam Pharma's Phase 3 trial for Obicetrapib demonstrated significant LDL-C reduction and a good safety profile, which could positively impact the stock price.
The significant reduction in LDL-C levels and the positive safety profile of Obicetrapib are likely to boost investor confidence in NewAmsterdam Pharma, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100